Format

Send to

Choose Destination
J Subst Abuse Treat. 2013 May-Jun;44(5):473-80. doi: 10.1016/j.jsat.2012.10.004. Epub 2012 Dec 3.

Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes.

Author information

1
National Development and Research Institutes, New York, NY 10010, USA. matusow@ndri.org

Abstract

Drug treatment courts are an increasingly important tool in reducing the census of those incarcerated for non-violent drug offenses; medication assisted treatment (MAT) is proven to be an effective treatment for opioid addiction. However, little is known about the availability of and barriers to MAT provision for opioid-addicted people under drug court jurisdiction. Using an online survey, we assessed availability, barriers, and need for MAT (especially agonist medication) for opioid addiction in drug courts. Ninety-eight percent reported opioid-addicted participants, and 47% offered agonist medication (56% for all MAT including naltrexone). Barriers included cost and court policy. Responses revealed significant uncertainty, especially among non-MAT providing courts. Political, judicial and administrative opposition appear to affect MAT's inconsistent use and availability in drug court settings. These data suggest that a substantial, targeted educational initiative is needed to increase awareness of the treatment and criminal justice benefits of MAT in the drug courts.

PMID:
23217610
PMCID:
PMC3602216
DOI:
10.1016/j.jsat.2012.10.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center